PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3171246-0 1988 The long-term stability of recombinant (serine-17) human interferon-beta. Serine 40-46 interferon beta 1 Homo sapiens 57-72 2514233-1 1989 The in vitro effects of recombinant human interferon-beta ser (rIFN-beta ser) and 3"-azido-3"-deoxythymidine (AZT) alone and in combination on human immunodeficiency virus (HIV) replication were examined. Serine 58-61 interferon beta 1 Homo sapiens 42-57 2472488-8 1989 These alterations after sc administration were similar quantitatively to those resulting from the same dose of IFN-beta ser given iv. Serine 120-123 interferon beta 1 Homo sapiens 111-119 2624146-3 1989 While cells in FBS-SM show a substantially greater increase in 2-5A synthetase by IFN-beta ser than cells in SFN-SM, the latter culture condition is significantly more effective in elevating synthetase activity with the addition of IFN-alpha 2. Serine 91-94 interferon beta 1 Homo sapiens 82-90 2785576-0 1989 Enhancement of indoleamine 2,3-dioxygenase activity in cancer patients receiving interferon-beta Ser. Serine 97-100 interferon beta 1 Homo sapiens 81-96 2785576-4 1989 bolus injection of 90 X 10(6) units or 180 X 10(6) units of IFN-beta Ser, were cultivated in medium containing [3H]tryptophan. Serine 69-72 interferon beta 1 Homo sapiens 60-68 2785576-6 1989 Significantly enhanced IDO activity was observed after IFN-beta Ser treatment, with a mean paired increase of 43% of maximum inducible activity. Serine 64-67 interferon beta 1 Homo sapiens 55-63 3230332-2 1988 These were used to study the in vitro anti-proliferative effects of a recombinant DNA human interferon-beta (rIFN-beta ser). Serine 119-122 interferon beta 1 Homo sapiens 92-107 2809278-0 1989 Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser. Serine 91-94 interferon beta 1 Homo sapiens 75-90 3171246-1 1988 Escherichia coli-derived (Serine 17) human interferon-beta (HuIFN-beta SER) was formulated with SDS and placed at multiple isothermal temperatures (-70 degrees C to 37 degrees C). Serine 26-32 interferon beta 1 Homo sapiens 43-58 3171246-1 1988 Escherichia coli-derived (Serine 17) human interferon-beta (HuIFN-beta SER) was formulated with SDS and placed at multiple isothermal temperatures (-70 degrees C to 37 degrees C). Serine 71-74 interferon beta 1 Homo sapiens 43-58 2960673-0 1987 Binding of recombinant-produced interferon beta ser to human lymphoblastoid cells. Serine 48-51 interferon beta 1 Homo sapiens 32-47 3045221-1 1988 Interferon-beta serine (IFN-beta ser) was administered intravenously (i.v.) Serine 16-22 interferon beta 1 Homo sapiens 0-15 3045221-1 1988 Interferon-beta serine (IFN-beta ser) was administered intravenously (i.v.) Serine 16-19 interferon beta 1 Homo sapiens 0-15 3045221-3 1988 In this Phase I trial, IFN-beta ser was tolerated without limiting fever or subjective toxicities. Serine 32-35 interferon beta 1 Homo sapiens 23-31 2839097-4 1988 IFN-beta ser induced a greater than or equal to 50% reduction in the 7 day growth of 6 of the 15 cultures. Serine 9-12 interferon beta 1 Homo sapiens 0-8 2839097-7 1988 In contrast, when treated with the combination of IFN-beta ser plus IFN-gamma, 1000 Units/ml of each interferon preparation, 12 of 15 cultures were inhibited by greater than or equal to 50% after 7 days growth. Serine 59-62 interferon beta 1 Homo sapiens 50-58 2839097-9 1988 One glioblastoma culture, G-7, was studied through 45 passages and displayed the same sensitivity at different passages to growth inhibition when exposed to IFN-beta ser, IFN-gamma or both interferons. Serine 166-169 interferon beta 1 Homo sapiens 157-165 2960673-3 1987 At 37 degrees C, binding of 125I IFN beta ser occurred rapidly (t1/2max less than or equal to 15 min) followed by internalization and degradation of bound ligand. Serine 42-45 interferon beta 1 Homo sapiens 33-41 2960673-5 1987 Dissociation of bound 125I IFN beta ser from Daudi cells was slow (t1/2 = 1.2 h) of bound radiolabeled ligand was observed in the presence of unlabeled IFN beta ser, naturally produced IFN beta, and IFN alpha 6, but was not observed with unlabeled IFN gamma or nonspecific proteins. Serine 36-39 interferon beta 1 Homo sapiens 27-35 2960673-5 1987 Dissociation of bound 125I IFN beta ser from Daudi cells was slow (t1/2 = 1.2 h) of bound radiolabeled ligand was observed in the presence of unlabeled IFN beta ser, naturally produced IFN beta, and IFN alpha 6, but was not observed with unlabeled IFN gamma or nonspecific proteins. Serine 36-39 interferon beta 1 Homo sapiens 152-160 2960673-5 1987 Dissociation of bound 125I IFN beta ser from Daudi cells was slow (t1/2 = 1.2 h) of bound radiolabeled ligand was observed in the presence of unlabeled IFN beta ser, naturally produced IFN beta, and IFN alpha 6, but was not observed with unlabeled IFN gamma or nonspecific proteins. Serine 36-39 interferon beta 1 Homo sapiens 152-160 2960673-5 1987 Dissociation of bound 125I IFN beta ser from Daudi cells was slow (t1/2 = 1.2 h) of bound radiolabeled ligand was observed in the presence of unlabeled IFN beta ser, naturally produced IFN beta, and IFN alpha 6, but was not observed with unlabeled IFN gamma or nonspecific proteins. Serine 116-119 interferon beta 1 Homo sapiens 27-35 2960673-6 1987 Concomitantly, equilibrium analysis indicated heterogeneous binding of 125I IFN beta ser to six cell lines of lymphoid origin consistent with either negative cooperativity or two populations of receptors. Serine 85-88 interferon beta 1 Homo sapiens 76-84 2960673-7 1987 Analysis of binding of 125I IFN beta ser to Daudi cell receptors in the presence of unlabeled IFN alpha 6 suggested that one receptor served both ligands. Serine 37-40 interferon beta 1 Homo sapiens 28-36 2960673-9 1987 This complex was absent when binding occurred in the presence of either excess unlabeled IFN beta ser or IFN alpha 6. Serine 98-101 interferon beta 1 Homo sapiens 89-97 3115570-11 1987 We conclude that combinations of IFN-beta ser and IFN-gamma can be safely administered on a chronic basis without enhanced or cumulative toxic effects. Serine 42-45 interferon beta 1 Homo sapiens 33-41 3079540-3 1987 IFN-beta ser affected lipoprotein lipids of patients in a dose dependent fashion. Serine 9-12 interferon beta 1 Homo sapiens 0-8 3079540-8 1987 A dose-related increase in plasma triglyceride concentration occurred during IFN-beta ser, increasing 74% for patients on low dose and 136% for patients on high doses. Serine 86-89 interferon beta 1 Homo sapiens 77-85 3079540-9 1987 This increase was only observed after 9 days on IFN-beta ser. Serine 25-28 interferon beta 1 Homo sapiens 48-56 3756886-1 1986 Beta-interferon serine (IFN-beta ser) is a genetically altered recombinant IFN with a specific activity of 2 X 10(8) IU/mg protein. Serine 16-22 interferon beta 1 Homo sapiens 24-32 3039014-0 1987 Potency stability of recombinant (Serine-17) human interferon-beta. Serine 34-40 interferon beta 1 Homo sapiens 51-66 3039014-1 1987 The antiviral activity of Escherichia coli-derived (Serine-17) human interferon-beta, formulated with human serum albumin, is stable for 2 years when lyophilized and stored under refrigeration. Serine 52-58 interferon beta 1 Homo sapiens 69-84 2437222-7 1986 Overall, however, none of the IFNs was markedly more effective in antiproliferative effects than any other, although there was a trend toward IFN-beta ser having more potent antiproliferative properties when compared to IFN-alpha 2 (p = 0.055). Serine 151-154 interferon beta 1 Homo sapiens 142-150 2437222-8 1986 Twelve of 13 tumors exposed to combinations of IFN-beta ser and IFN-gamma demonstrated a synergistic antiproliferative effect. Serine 56-59 interferon beta 1 Homo sapiens 47-55 3308083-0 1987 Open-label phase II trial of recombinant beta interferon (IFN-beta (ser)) in patients with colorectal cancer. Serine 68-71 interferon beta 1 Homo sapiens 58-66 2957045-0 1987 Variation in the binding of 125I-labeled interferon-beta ser to cellular receptors during growth of human renal and bladder carcinoma cells in vitro. Serine 57-60 interferon beta 1 Homo sapiens 41-56 2957045-1 1987 Studies of various established human bladder and renal carcinoma cell lines cultured in vitro demonstrated the presence of specific, saturable, high affinity binding sites for 125I-labeled human interferon Beta ser IFN-beta ser). Serine 211-214 interferon beta 1 Homo sapiens 215-223 2957045-1 1987 Studies of various established human bladder and renal carcinoma cell lines cultured in vitro demonstrated the presence of specific, saturable, high affinity binding sites for 125I-labeled human interferon Beta ser IFN-beta ser). Serine 224-227 interferon beta 1 Homo sapiens 215-223 2957045-3 1987 A single class of binding sites (1000-2000/cell) with an affinity constant of 10(10)-10(11) L/M was measured at 4 degrees C for cells exhibiting widely different sensitivity to the antiproliferative effect of IFN-beta ser. Serine 218-221 interferon beta 1 Homo sapiens 209-217 2957045-4 1987 Major fluctuations in the binding of 125I-labeled IFN-beta ser to cellular receptors were observed during in vitro proliferation of four of five cell lines examined. Serine 59-62 interferon beta 1 Homo sapiens 50-58 2957045-6 1987 Cell cycle analysis suggested that within the first 24 h and in the very late log and stationary phase of growth of ACHN (human renal carcinoma) cells, variations in the binding of 125I-labeled IFN-beta ser were partially attributable to binding fluctuations during the mitotic cycle. Serine 203-206 interferon beta 1 Homo sapiens 194-202 2957045-8 1987 T24 (human transitional cell carcinoma) and ACHN cells, synchronized by serum starvation, demonstrated increased binding of 125I-labeled IFN-beta ser 4-16 h following serum replenishment. Serine 72-75 interferon beta 1 Homo sapiens 137-145 2957045-13 1987 These changes in the biological activity of this interferon corresponded to growth related fluctuations in the IFN-beta ser binding. Serine 120-123 interferon beta 1 Homo sapiens 111-119 3567933-1 1987 Interferon-beta-serine (IFN-beta ser) is a recombinant genetically altered interferon with extensive in vitro antiproliferative, antiviral, and immunological effects. Serine 16-22 interferon beta 1 Homo sapiens 24-32 3567933-1 1987 Interferon-beta-serine (IFN-beta ser) is a recombinant genetically altered interferon with extensive in vitro antiproliferative, antiviral, and immunological effects. Serine 16-19 interferon beta 1 Homo sapiens 24-32 3567933-3 1987 IFN-beta ser was given twice weekly (Monday/Thursday) by a 4-h i.v. Serine 9-12 interferon beta 1 Homo sapiens 0-8 3567933-7 1987 Preliminary studies with normal donor cells demonstrated that IFN-beta ser in vitro enhanced activity in a mononuclear-MBL-2 growth inhibition, NK-cell, and monocyte antibody-dependent cellular cytotoxicity assay. Serine 71-74 interferon beta 1 Homo sapiens 62-70 3567933-13 1987 In general changes in these assays were observed at low levels of IFN-beta ser, increased at 4-48 h, then returned toward base line. Serine 42-45 interferon beta 1 Homo sapiens 66-74 3567933-14 1987 We conclude that IFN-beta ser is an active biological agent in vitro and significantly modulated the biological responses in patients with renal cell carcinoma. Serine 26-29 interferon beta 1 Homo sapiens 17-25 3756886-1 1986 Beta-interferon serine (IFN-beta ser) is a genetically altered recombinant IFN with a specific activity of 2 X 10(8) IU/mg protein. Serine 16-19 interferon beta 1 Homo sapiens 24-32 3756886-3 1986 IFN-beta ser was given by a 4-h intravenous infusion twice weekly (Monday and Thursday). Serine 9-12 interferon beta 1 Homo sapiens 0-8 3756886-14 1986 We conclude that IFN-beta ser is a well tolerated IFN with minimal renal, hepatic, and bone marrow toxicity. Serine 26-29 interferon beta 1 Homo sapiens 17-25 3014018-0 1986 Interferon-beta ser as prophylaxis against experimental rhinovirus infection in volunteers. Serine 16-19 interferon beta 1 Homo sapiens 0-15 3016203-2 1986 Interferon beta ser, but not alpha 76, potentiated the destruction mediated by interleukin-2 (IL-2) dependent, long-term T cell cultures. Serine 16-19 interferon beta 1 Homo sapiens 0-15 3016203-4 1986 In contrast to the potentiation of T cell-mediated cytotoxicity, IFN beta ser and alpha 76 did not modulate the cytotoxic activity of cytotoxic T cell clones that are specifically reactive to autologous EBV-LCL. Serine 74-77 interferon beta 1 Homo sapiens 65-73 3016203-6 1986 Rather, our results are consistent with IFN beta ser augmenting cytotoxic T cell reactivity indirectly, possibly via its influence on other immunoregulatory cells. Serine 49-52 interferon beta 1 Homo sapiens 40-48 3016203-7 1986 Although the precise mechanism whereby IFN beta ser may potentiate cytotoxicity is not yet defined, the synergistic action of IFN beta ser and IL-2 on long-term CTL cultures offers an alternate means to selectively enhance a desirable cytotoxic response. Serine 48-51 interferon beta 1 Homo sapiens 39-47 3016203-7 1986 Although the precise mechanism whereby IFN beta ser may potentiate cytotoxicity is not yet defined, the synergistic action of IFN beta ser and IL-2 on long-term CTL cultures offers an alternate means to selectively enhance a desirable cytotoxic response. Serine 135-138 interferon beta 1 Homo sapiens 126-134 3014018-1 1986 The first test of intranasal recombinant human interferon-beta ser (IFN-beta ser) as prophylaxis against common colds is reported. Serine 63-66 interferon beta 1 Homo sapiens 47-62 3014018-1 1986 The first test of intranasal recombinant human interferon-beta ser (IFN-beta ser) as prophylaxis against common colds is reported. Serine 63-66 interferon beta 1 Homo sapiens 68-76 3014018-2 1986 IFN-beta ser was cleared from the nose like IFN-alpha. Serine 9-12 interferon beta 1 Homo sapiens 0-8 3014018-3 1986 A total of 10 volunteers were each given a total of 2.6 X 10(7) units of IFN-beta ser as 13 doses administered three times daily over 4 days and there were negligible symptoms that were not significantly different from those in 10 given placebo. Serine 82-85 interferon beta 1 Homo sapiens 73-81 29431732-5 2018 Specifically, blocking AhR redirected IFN-beta signaling to STAT3 phosphorylation through both tyrosine and serine sites, which subsequently facilitated STAT3 nuclear translocation and subsequent binding to the p53 promoter in the nucleus. Serine 108-114 interferon beta 1 Homo sapiens 38-46 2416427-3 1986 In all cell lines except one, the addition of IFN-gamma to either IFN-alpha 54 or IFN-beta ser resulted in a synergistic antiproliferative effect, regardless of individual IFN sensitivities or tissue of origin. Serine 91-94 interferon beta 1 Homo sapiens 82-90 2416427-8 1986 The addition of IFN-alpha 54 to IFN-beta ser in the SKCO 1 cell line resulted in an antagonistic interaction. Serine 41-44 interferon beta 1 Homo sapiens 32-40 2416427-9 1986 Timing experiments with RT112 cells indicate that IFN-gamma and IFN-beta ser need not be in the media at the same time for the synergistic effect to occur. Serine 73-76 interferon beta 1 Homo sapiens 64-72 6091102-3 1984 The resulting interferon, IFN-beta Ser-17, retains the antiviral, natural killer cell activation, and antiproliferative activities of native fibroblast interferon. Serine 35-38 interferon beta 1 Homo sapiens 26-34 6091102-3 1984 The resulting interferon, IFN-beta Ser-17, retains the antiviral, natural killer cell activation, and antiproliferative activities of native fibroblast interferon. Serine 35-38 interferon beta 1 Homo sapiens 141-162 6091102-4 1984 The purified IFN-beta Ser-17 protein has an antiviral specific activity of 2 X 10(8) units/mg, similar to that of purified native fibroblast interferon. Serine 22-25 interferon beta 1 Homo sapiens 13-21 33603735-5 2020 O-GlcNAcylation of the serine-rich region of MAVS also suppresses its interaction with TRAF3; this prevents IRF3 activation and production of interferon-beta. Serine 23-29 interferon beta 1 Homo sapiens 142-157 20406818-0 2010 Negative role of RIG-I serine 8 phosphorylation in the regulation of interferon-beta production. Serine 23-29 interferon beta 1 Homo sapiens 69-84 24531619-6 2014 IFN-beta treatment also activated DAPK1 by decreasing its phosphorylation level at serine 308. Serine 83-89 interferon beta 1 Homo sapiens 0-8 27426928-4 2016 Interestingly, difference from the human ELF4 (huELF4), poELF4 mutants lacking the serine/threonine rich domain, which has been demonstrated to be responsible for the phosphorylation of huELF4, were still capable of activating IFN-beta promoter. Serine 83-89 interferon beta 1 Homo sapiens 227-235 21478011-11 2011 For IFNbeta 100 IU/ml the SER was 1.72 for in MiaPaca-2 and 1.51 in Panc-1. Serine 26-29 interferon beta 1 Homo sapiens 4-11 20406818-4 2010 Here, we report the identification of serine 8 phosphorylation at the first CARD of RIG-I as a negative regulatory mechanism of RIG-I-mediated IFN-beta production. Serine 38-44 interferon beta 1 Homo sapiens 143-151 16226271-11 2005 Indeed, variations in potency estimates for preparations containing IFN-beta Ser 17 mutein were sufficiently large to indicate that assays could distinguish preparations of IFN-beta Ser 17 mutein from preparations of glycosylated IFN-beta. Serine 182-185 interferon beta 1 Homo sapiens 173-181 16226271-10 2005 However, greater inter-laboratory variations in estimates were evident from comparisons of Gb23-902-531 or 00/572 with either the 1st IS for E. coli-derived, non-glycosylated, IFN-beta with serine substitution at position 17 (IFN-beta Ser 17 mutein), Gxb02-901-535, or with a CIS (00/574) containing IFN-beta Ser 17 mutein. Serine 190-196 interferon beta 1 Homo sapiens 176-184 16226271-11 2005 Indeed, variations in potency estimates for preparations containing IFN-beta Ser 17 mutein were sufficiently large to indicate that assays could distinguish preparations of IFN-beta Ser 17 mutein from preparations of glycosylated IFN-beta. Serine 182-185 interferon beta 1 Homo sapiens 173-181 15752772-6 2005 The SD.IFN-beta also induced p53 and phosphorylation of p53 at Ser(15). Serine 63-66 interferon beta 1 Homo sapiens 7-15 11955727-7 2002 Betaseron (recombinant human interferon beta(ser), rHuIFN-beta(ser),) was the chosen preparation of beta-interferon. Serine 4-7 interferon beta 1 Homo sapiens 29-44 15728510-7 2005 Although both inhibitors of PI3K and MEK1 diminished the Ser(727) phosphorylation of STAT1 induced by IFN-beta, only Ly294002 inhibited sIL-1Ra production. Serine 57-60 interferon beta 1 Homo sapiens 102-110 12759354-4 2003 Our data demonstrate that p70 S6K is rapidly phosphorylated on threonine 421 and serine 424 and is activated during treatment of cells with IFNalpha or IFNbeta. Serine 81-87 interferon beta 1 Homo sapiens 152-159 12068083-13 2002 Additionally, IFNbeta induced Stat1 phosphorylation at both tyrosine 701 (Y701) and serine 727 (S727) residues. Serine 84-90 interferon beta 1 Homo sapiens 14-21 10918594-0 2000 IFN-beta induces serine phosphorylation of Stat-1 in Ewing"s sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Serine 17-23 interferon beta 1 Homo sapiens 0-8 11884587-6 2002 A neutralizing antibody against beta interferon (IFN-beta) blunted Ser(727) phosphorylation and apoptosis after 7kchol treatment; cells deficient in an IFN-beta receptor subunit exhibited blunted apoptosis. Serine 67-70 interferon beta 1 Homo sapiens 32-57 11884587-6 2002 A neutralizing antibody against beta interferon (IFN-beta) blunted Ser(727) phosphorylation and apoptosis after 7kchol treatment; cells deficient in an IFN-beta receptor subunit exhibited blunted apoptosis. Serine 67-70 interferon beta 1 Homo sapiens 49-57 11846976-3 2002 In infected cells, these factors are activated by phosphorylation on the serine residues, transported to the nucleus, where they bind to the promoters of IFNA and IFNB genes and tether histone transacetylases to the transcription complex enhanceosome. Serine 73-79 interferon beta 1 Homo sapiens 163-167 10918594-4 2000 Interestingly, an additional rapid phosphorylation of Stat-1 on serine was observed after IFN-beta treatment, with concomitant activation of p38 mitogen-activated protein kinase. Serine 64-70 interferon beta 1 Homo sapiens 90-98 8892645-9 1996 Both single and multiple doses of IFN-beta(ser) increased serum ISG15 levels significantly (p < 0.01) over baseline. Serine 43-46 interferon beta 1 Homo sapiens 34-42 10363567-13 1999 The maximal sensitizing enhancement ratio (SER) obtained with n-IFN-beta or r-IFN-beta1a at 3000 IU/ml was 1.66 and 1.51, respectively. Serine 43-46 interferon beta 1 Homo sapiens 64-72 9815298-1 1998 BACKGROUND: Preclinical and early clinical trials suggested that the biologic agent interferon beta ser (IFN beta ser) may augment the anticancer activity of 5-fluorouracil (5-FU). Serine 100-103 interferon beta 1 Homo sapiens 84-99 9815298-1 1998 BACKGROUND: Preclinical and early clinical trials suggested that the biologic agent interferon beta ser (IFN beta ser) may augment the anticancer activity of 5-fluorouracil (5-FU). Serine 100-103 interferon beta 1 Homo sapiens 105-113 9815298-15 1998 CONCLUSIONS: The combination of 5-FU and IFN beta ser was active in patients with advanced colorectal carcinoma, and survival with this regimen was comparable to or better than that with other modulating regimens. Serine 50-53 interferon beta 1 Homo sapiens 41-49 21533466-4 1997 However, all NSCLC lines were resistant to the antiproliferative effects of IFN alpha 2 and IFN beta ser. Serine 101-104 interferon beta 1 Homo sapiens 92-100 8892645-10 1996 A maximum 7.3-fold enhancement of serum ISG15 was obtained after multiple injections of 8 million units of IFN-beta(ser). Serine 34-37 interferon beta 1 Homo sapiens 107-115 8069001-1 1994 OBJECTIVE: To introduce readers to the use of a new agent, interferon beta-1b (IFN beta ser), in the treatment of relapsing-remitting multiple sclerosis (RRMS). Serine 88-91 interferon beta 1 Homo sapiens 59-74 7553067-8 1995 Pre-exposure in vivo to IFN-beta ser seems to prime the PBMs to respond to in vitro stimulation by IFN-gamma, which otherwise had no effect. Serine 33-36 interferon beta 1 Homo sapiens 24-32 7553067-10 1995 All the NK activity responding to IFN-beta ser was found in the CD16+ enriched population of PBM, suggesting that it is unlikely that in vivo redistribution of CD16+ subsets representative of NK cells has occurred in the peripheral blood. Serine 43-46 interferon beta 1 Homo sapiens 34-42 7523670-7 1994 Interferon beta ser had weak IDO stimulatory activity that was in a few cases additive to that of IFN-gamma. Serine 16-19 interferon beta 1 Homo sapiens 0-15 8069001-1 1994 OBJECTIVE: To introduce readers to the use of a new agent, interferon beta-1b (IFN beta ser), in the treatment of relapsing-remitting multiple sclerosis (RRMS). Serine 88-91 interferon beta 1 Homo sapiens 79-87 8069001-2 1994 Therapeutic and economic issues surrounding IFN beta ser are discussed, as are its pharmacology, clinical efficacy, adverse effects, and dosage guidelines. Serine 53-56 interferon beta 1 Homo sapiens 44-52 8069001-6 1994 DATA SYNTHESIS: IFN beta ser has recently been approved by the Food and Drug Administration for the treatment of RRMS. Serine 25-28 interferon beta 1 Homo sapiens 16-24 8069001-14 1994 CONCLUSIONS: IFN beta ser is not a cure for MS, but it is well tolerated and patients with RRMS have shown significant improvements in exacerbation rates and burden of central nervous system disease. Serine 22-25 interferon beta 1 Homo sapiens 13-21 8483840-0 1993 Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin. Serine 54-57 interferon beta 1 Homo sapiens 38-53 8301155-5 1993 Sixty to 120 min after IFN-beta ser injection median levels of cortisol, adrenocorticotropin (ACTH), prolactin (PRL), and growth hormone (GH) rose two-fold. Serine 32-35 interferon beta 1 Homo sapiens 23-31 8301155-6 1993 Urinary free cortisol excretion increased significantly during the day following IFN-beta ser administration. Serine 90-93 interferon beta 1 Homo sapiens 81-89 8483840-1 1993 The pharmacokinetics of and biologic response modification by recombinant human interferon-beta ser (rIFN-beta ser) were evaluated in 12 healthy male volunteers. Serine 96-99 interferon beta 1 Homo sapiens 80-95 8483840-1 1993 The pharmacokinetics of and biologic response modification by recombinant human interferon-beta ser (rIFN-beta ser) were evaluated in 12 healthy male volunteers. Serine 111-114 interferon beta 1 Homo sapiens 80-95 1289413-4 1992 In the second study, patients received IFN-beta ser 180 million units t.i.w. Serine 48-51 interferon beta 1 Homo sapiens 39-47 1289413-6 1992 Severe or life-threatening fatigue with decline in performance status complicated treatment of 37% of patients receiving IFN-alpha 2b and 17% of patients receiving IFN-beta ser. Serine 173-176 interferon beta 1 Homo sapiens 164-172 1907881-5 1991 IFN-gamma and IFN-beta ser alone or in combination significantly increased serum TAG-72 or CEA in approximately 65% of those patients. Serine 23-26 interferon beta 1 Homo sapiens 14-22 1525120-5 1992 In normal subjects, IFN-beta serine reduced LDL cholesterol and apolipoprotein (apo) B levels by 25% and 27%, respectively (p less than 0.05); LDL apo B synthesis was decreased by 59% (p less than 0.05). Serine 29-35 interferon beta 1 Homo sapiens 20-28 1525120-6 1992 In hypercholesterolemic subjects, IFN-beta serine reduced LDL cholesterol levels by 38% (p less than 0.05); however, apo B concentrations and production rates were not significantly decreased. Serine 43-49 interferon beta 1 Homo sapiens 34-42 2086672-0 1990 Biological and clinical effects of interferon-beta ser at two doses. Serine 51-54 interferon beta 1 Homo sapiens 35-50 1708891-1 1991 The location of biologically relevant epitopes on recombinant human beta interferon in which Ser-17 replaces Cys-17 (rh[Ser17]IFN-beta) was evaluated by testing the immunoreactivity of antibodies against 159 sequential, overlapping octamer peptides. Serine 93-96 interferon beta 1 Homo sapiens 126-134 2395002-7 1990 The p78 protein was induced in a dose-dependent manner by IFN-alpha and IFN-beta ser. Serine 81-84 interferon beta 1 Homo sapiens 72-80 2273299-4 1990 IFN-beta ser at this dose and schedule does not appear to be an active single agent for patients with refractory malignant mesothelioma. Serine 9-12 interferon beta 1 Homo sapiens 0-8 2395002-5 1990 IDO activity was induced by IFN-gamma and the combination of IFN-beta ser and IFN-gamma, but not IFN-beta ser alone. Serine 70-73 interferon beta 1 Homo sapiens 61-69 2086672-7 1990 When assessed 24 h after IFN-beta ser at 4.5 x 10(6) units, significant (p less than 0.05) augmentation had occurred in beta 2-microglobulin, HLA-DR, and HLA-DQ expression on monocytes, 2",5"-oligoadenylate (2-5A) synthetase in peripheral mononuclear cells, and natural killer (NK) and K cells functional activity. Serine 34-37 interferon beta 1 Homo sapiens 25-33 2120284-4 1990 IFN-beta ser was more effective than IFN-gamma in enhancing 2-5A synthetase activity (P = 0.001). Serine 9-12 interferon beta 1 Homo sapiens 0-8 2120284-6 1990 The combination enhanced tryptophan catabolism more effectively than IFN-beta ser in a dose-dependent manner (P less than 0.03). Serine 78-81 interferon beta 1 Homo sapiens 69-77 2120284-13 1990 Thus, IFN-beta ser and IFN-gamma each resulted in effective and essentially equivalent patterns of induction of induced proteins. Serine 15-18 interferon beta 1 Homo sapiens 6-14 1698636-1 1990 The use of a panel of monoclonal antibodies (mAb) raised against recombinant (serine-17) human interferon-beta (rHuIFN-beta ser) has permitted the identification of three epitopes on HuIFN-beta, designated as sites I, II and III, based solely on functional differences, i.e., the neutralization of antiviral and antiproliferative activities of natural and recombinant HuIFN-beta (Redlich, P.N. Serine 78-84 interferon beta 1 Homo sapiens 95-110 1698636-1 1990 The use of a panel of monoclonal antibodies (mAb) raised against recombinant (serine-17) human interferon-beta (rHuIFN-beta ser) has permitted the identification of three epitopes on HuIFN-beta, designated as sites I, II and III, based solely on functional differences, i.e., the neutralization of antiviral and antiproliferative activities of natural and recombinant HuIFN-beta (Redlich, P.N. Serine 78-81 interferon beta 1 Homo sapiens 95-110 2395002-8 1990 IFN-gamma enhanced the expression of p78 induction by IFN-alpha or IFN-beta ser, even at concentrations of IFN-gamma that did not induce the protein when administered as a single agent. Serine 76-79 interferon beta 1 Homo sapiens 67-75 2395002-9 1990 The combination of IFN-alpha and IFN-beta ser, which results in an antagonistic antiproliferative effect, also resulted in an antagonistic induction of p78. Serine 42-45 interferon beta 1 Homo sapiens 33-41 2395002-11 1990 Thus, the synergistic antiproliferative effect produced by IFN-beta ser and IFN-gamma in SKCO 1 cells could not be correlated with a synergistic enhancement in 2-5A synthetase or IDO activity, or with a perturbation in the cell cycle. Serine 68-71 interferon beta 1 Homo sapiens 59-67 2395002-12 1990 In contrast, the combination of IFN-gamma and IFN-alpha or IFN-beta ser synergistically enhanced the expression of p78 protein in these cells. Serine 68-71 interferon beta 1 Homo sapiens 59-67 1895445-2 1991 IFN beta ser inhibited growth of anchorage dependent semiconfluent monolayers and anchorage dependent colony formation of both DU-145 and PC-3 in a dose dependent manner but had no effect on LNCaP. Serine 9-12 interferon beta 1 Homo sapiens 0-8 2136700-8 1990 However, it is unlikely that differences in binding and internalization of this magnitude play a primary role in the synergistic antiproliferative effect of IFN-gamma with IFN-beta ser in SKCO1 cells. Serine 181-184 interferon beta 1 Homo sapiens 172-180 1895445-7 1991 The potential use of IFN beta ser in combination with hormonal therapy to delay the development of hormone refractory tumors is discussed. Serine 30-33 interferon beta 1 Homo sapiens 21-29 2082958-8 1990 IFN-beta ser appears to have activity in human glioma and is well tolerated at this dosage and schedule. Serine 9-12 interferon beta 1 Homo sapiens 0-8 2140395-11 1990 These data do suggest that, for human glioma cells in culture, type I IFN receptors may display a subtle architectural variation that allows equivalent binding of both IFN-alpha and IFN-beta ser, but allows an enhanced signal transduction and biological effect only after binding a specific IFN subtype. Serine 191-194 interferon beta 1 Homo sapiens 182-190 2136700-1 1990 Combination treatment of SKCO1 human colon carcinoma cells with beta ser-interferon (IFN-beta ser) and gamma-interferon (IFN-gamma) results in a synergistic antiproliferative effect. Serine 69-72 interferon beta 1 Homo sapiens 85-93 2136700-2 1990 The role of IFN-beta ser and IFN-gamma receptor modulation was investigated as a possible mechanism for this response. Serine 21-24 interferon beta 1 Homo sapiens 12-20 2136700-3 1990 IFN-gamma (0.05-50 ng/ml) pretreatment of SKCO1 cells for 24 h decreased specific binding of 125I-IFN-beta ser by 35-60%. Serine 107-110 interferon beta 1 Homo sapiens 98-106 2136700-5 1990 In contrast, pretreatment of SKCO1 cells with IFN-beta ser (5 ng/ml) resulted in slight (10-35%) increases in 125I-IFN-gamma-specific binding. Serine 55-58 interferon beta 1 Homo sapiens 46-54 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 91-94 interferon beta 1 Homo sapiens 82-90 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 91-94 interferon beta 1 Homo sapiens 167-175 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 91-94 interferon beta 1 Homo sapiens 167-175 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 176-179 interferon beta 1 Homo sapiens 82-90 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 176-179 interferon beta 1 Homo sapiens 167-175 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 176-179 interferon beta 1 Homo sapiens 167-175 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 176-179 interferon beta 1 Homo sapiens 82-90 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 176-179 interferon beta 1 Homo sapiens 167-175 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 176-179 interferon beta 1 Homo sapiens 167-175 2136700-7 1990 125I-IFN-gamma internalization studies performed at 37 degrees C confirmed the cell surface binding assays; IFN-beta ser-treated cells internalized 30-50% more labeled IFN-gamma than untreated cells. Serine 117-120 interferon beta 1 Homo sapiens 108-116 1895445-4 1991 The combination of TGF beta 1 and IFN beta ser was additive in its effects on growth. Serine 43-46 interferon beta 1 Homo sapiens 34-42